XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Inventory
 6 Months Ended
Jun. 30, 2023
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consisted of the following as of June 30, 2023 and December 31, 2022:
(in thousands)June 30,
2023		December 31, 2022
Current assets
Work-in-process$— $23 
Finished goods1,080 1,171 
Total inventory, current$1,080 $1,194 
Non-Current assets
Raw materials$1,043 $1,043 
Work-in-process7,260 8,212 
Finished goods798 1,041 
Total inventory, non-current9,101 10,296 
Total inventory$10,181 $11,490 
Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company evaluates the risk of excess inventory and product expiry by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, patient usage, and generic competition. The Company’s inventory balance consisted of $7.1 million and $8.0 million of HETLIOZ® product and $3.0 million and $3.4 million of Fanapt® product as of June 30, 2023 and December 31, 2022, respectively.